Peer Reviewed
Complementary medicine update

Lipoic acid for Alzheimer’s disease

Gerald Münch, Lynne Shinto, Annette Maczurek
Abstract
Two open trials in Germany and a pilot double-blind, randomised placebo-controlled trial in the USA might suggest a long-term substantial benefit for lipoic acid in treating Alzheimer’s disease.
Key Points

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that destroys patient memory and cognition, communication skills and ability to perform activities of daily living. It affects up to 40% of people over 85 years of age. Despite extensive research into the pathogenesis of AD, a neuroprotective treatment is still unavailable for clinical use – particularly for the early stages of disease.

    Alpha lipoic acid (LA), an antioxidant that has been registered as a medicine in Germany for diabetic neuropathy since 1966, might offer benefits for patients with AD.

Get full access
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?